Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis
Graefe's Archive for Clinical and Experimental Ophthalmology · 2024
DOI: 10.1007/s00417-024-06460-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Graefe's Archive for Clinical and Experimental Ophthalmology, 2024. Verfasst von Hironori Hosoya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Diabetic Retinopathy, Intravitreal Injections, Laser Coagulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, The University of Tokyo.
Abstract (Originalsprache)
Purpose
To evaluate the effects of subthreshold micropulse laser (SML) in addition to anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME).
Methods
MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were systematically searched for studies that compared anti-VEGF with SML and anti-VEGF monotherapy for DME. Outcome measures were best-corrected visual acuity (BCVA), central macular thickness (CMT), and the number of anti-VEGF injections.
Results
Eight studies including 493 eyes were selected. Four studies were randomized controlled, and the other four were retrospective. Meta-analysis showed that there was no significant difference in BCVA (mean difference [MD] -0.04; 95%CI -0.09 to 0.01 logMAR; P = 0.13;). CMT was thinner in the group of anti-VEGF with SML (MD -11.08; 95%CI -21.04 to -1.12 µm; P = 0.03); however, it was due to a single study that weighed higher, and the sensitivity and subcategory analyses did not support the finding. The number of anti-VEGF injections was significantly decreased in the group of anti-VEGF with SML (MD -2.22; 95%CI -3.02 to -1.42; P < 0.0001).
Conclusion
Current evidence indicates that adding SML to anti-VEGF therapy could significantly reduce the number of anti-VEGF injections compared to anti-VEGF monotherapy, while achieve similar BCVA and CMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan. ueta-tky@umin.ac.jp.
- Department of Ophthalmology, Kitasato University School of Medicine, Tokyo, Japan.
- Department of Ophthalmology, Showa General Hospital, Tokyo, Japan.
Förderung
- JSPS KAKENHI
- The University of Tokyo
Zitieren
APA
Hosoya, H., Ueta, T., Hirasawa, K., Toyama, T., & Shiraya, T. (2024). Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06460-7
Vancouver
Hosoya H, Ueta T, Hirasawa K, Toyama T, Shiraya T. Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024. doi:10.1007/s00417-024-06460-7
BibTeX
@article{Hosoya2024,
author = {Hosoya, Hironori and Ueta, Takashi and Hirasawa, Kazunori and Toyama, Taku and Shiraya, Tomoyasu},
title = {Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis},
journal = {Graefe's Archive for Clinical and Experimental Ophthalmology},
year = {2024},
doi = {10.1007/s00417-024-06460-7}
}
EUVIMED